- Conditions
- Venous Thromboembolism, Postpartum
- Interventions
- Dalteparin Sodium
- Drug
- Lead sponsor
- Ottawa Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Charlottesville, Virginia • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 1,207
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn, Streptococcal Infections
- Interventions
- Inhaled Prostaglandin E1
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 7 Days
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Palo Alto, California • Iowa City, Iowa + 7 more
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab combination therapy
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 10,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 102
- States / cities
- Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 71 more
- Conditions
- SARS-CoV-2
- Interventions
- REGN14256, imdevimab, casirivimab + imdevimab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 28
- States / cities
- La Mesa, California • Long Beach, California • Mission Viejo, California + 19 more
- Conditions
- Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
- Interventions
- Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
- Drug · Combination Product
- Lead sponsor
- Compugen Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more
- Conditions
- Follicular Lymphoma, Lymphoma
- Interventions
- Odronextamab
- Biological
- Lead sponsor
- Gottfried von Keudell, MD PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Brain Tumor, Recurrent
- Interventions
- Photofrin (porfimer sodium) & photodynamic therapy.
- Drug
- Lead sponsor
- Harry T Whelan, MD
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Wauwatosa, Wisconsin
- Conditions
- Pompe Disease
- Interventions
- Duvoglustat
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Bioequivalence
- Interventions
- Tacrolimus
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
- Interventions
- amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Rhinitis, Sinusitis
- Interventions
- Quinine Sulfate, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
- Interventions
- Naproxen, Acetaminophen, oxycodone, Gabapentin
- Drug
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Healthy Volunteer
- Interventions
- danoprevir, efavirenz, ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Dysferlinopathy
- Interventions
- rAAVrh74.MHCK7.DYSF.DV
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone, Ondansetron 16 MG
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- The Bronx, New York
- Conditions
- Gout, Hyperuricemia
- Interventions
- SAP-001
- Drug
- Lead sponsor
- Shanton Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Anaheim, California • DeLand, Florida • High Point, North Carolina
- Conditions
- Crohn Disease
- Interventions
- JNJ-64304500, Placebo, Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 37
- States / cities
- Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more
- Conditions
- Sleep Apnea
- Interventions
- Danavorexton, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • La Jolla, California + 14 more
- Conditions
- Glioblastoma
- Interventions
- Pembrolizumab and Temozolomide
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Human Immunodeficiency Virus
- Interventions
- 3-drug anti-HIV therapy, Raltegravir
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Months and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2038
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
- Interventions
- Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Salem, Massachusetts
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Interventions
- AMXT1501, DFMO
- Drug
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more